Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1.-122. (Cancelled)

123. (Currently Amended) A composition which comprises:

a) a conjugate of (i) ~~a ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion comprising an altered sphingosine base and~~ a derivative of a ganglioside, which ganglioside (1) is a GM2, GD2, GD3 lactone, O-acetyl GD3, or GT3 ganglioside and (2) comprises an unaltered sphingosine base, wherein the derivative differs from the ganglioside solely by having an altered sphingosine base which retains only C1 through C4 from the unaltered sphingosine base of the ganglioside, and (ii) Keyhole Limpet Hemocyanin, wherein the ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin by a stable amine bond between the C-4 carbon of the altered sphingosine base and a nitrogen of an ε-aminolysyl group of Keyhole Limpet Hemocyanin~~, an immunogenic protein-based carrier~~;

b) QS-21; ~~a saponin derivable from the bark of a Quillaja saponaria Molina tree;~~ and

c) a pharmaceutically acceptable carrier;

wherein the amount of the conjugated ganglioside derivative is an amount between about 1 µg and about 200 µg, the amount of ~~the saponin~~ QS-21 is an amount between about 10 µg and about 200 µg, ~~and when the ganglioside is GM2, the GM2:Keyhole Limpet Hemocyanin~~ the ganglioside:Keyhole Limpet Hemocyanin molar ratio is from 200:1 to 1400:1, and the relative amounts of such conjugate and ~~such saponin~~ QS-21 is ~~being~~ effective to stimulate or enhance production in a subject of an antibody to ~~whichever~~ the ganglioside, the ~~is present as a~~ derivative of which is present in the conjugate. [[,]]

~~wherein the ganglioside derivative is a derivative of a ganglioside selected from the group consisting of GM2, GD2, GD3 lactone, O-acetyl GD3 and GT3; and~~

~~wherein in the conjugate the ganglioside derivative is covalently bound to the Keyhole Limpet Hemocyanin by a stable amine bond between the C-4 carbon of the altered sphingosine base of the altered ceramide portion of the ganglioside derivative and the nitrogen of an ε-aminolysyl group of the Keyhole Limpet Hemocyanin.~~

124.-129. (Cancelled)

130. (Currently Amended) The composition of claim 123, wherein the amount of QS-21 ~~the saponin~~ is about ~~100~~ 50 µg.

131. (Currently Amended) The composition of claim 123 wherein the amount of QS-21 ~~the saponin~~ is about 200 µg.

132. (Currently Amended) The composition of claim 123 which comprises:

a) a conjugate of (i) ~~a ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion comprising an altered sphingosine base and~~ a derivative of a ganglioside, which ganglioside (1) is a GM2, GD2, GD3 lactone, O-acetyl GD3, or GT3 ganglioside and (2) comprises an unaltered sphingosine base, wherein the derivative differs from the ganglioside solely by having an altered sphingosine base which retains only C1 through C4 from the unaltered sphingosine base of the ganglioside, and (ii) Keyhole Limpet Hemocyanin, wherein the ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin by a stable amine bond between the C-4 carbon of the altered sphingosine base and a nitrogen of an ε-aminolysyl group of Keyhole Limpet Hemocyanin ~~an immunogenic protein-based carrier~~;

b) QS-21~~, a saponin derivable from the bark of a Quillaja saponaria Molina tree~~; and

c) a pharmaceutically acceptable carrier;

wherein the amount of the conjugated ganglioside derivative is ~~present in~~ an amount ~~of~~ between about 1 µg and about 200 µg, and the amount of QS-21 ~~the saponin~~ is about 100 µg, ~~and when the ganglioside is GM2, the GM2:Keyhole Limpet Hemocyanin~~ the ganglioside:Keyhole Limpet Hemocyanin molar ratio is from 200:1 to 1400:1, and wherein the relative amounts of such conjugate and ~~such saponin~~ QS-21 is effective to stimulate or enhance production in a subject of an antibody to GM2, GD2, GD3 and GT3, ~~whichever~~ the ganglioside, the ~~is present as a~~ derivative of which is present in the conjugate.[[,]]

~~wherein the ganglioside derivative is a derivative of a ganglioside selected from the group consisting of GM2, GD2, GD3 lactone, O-acetyl GD3 and GT3; and~~

~~wherein in the conjugate the ganglioside derivative is covalently bound to the Keyhole Limpet Hemocyanin by a stable amine bond between the C-4 carbon of the altered sphingosine base of the altered ceramide portion of the ganglioside derivative and the nitrogen of an ε-aminolysyl group of the Keyhole Limpet Hemocyanin.~~

133. (Previously Presented) A method of treating a subject afflicted with melanoma which comprises administering to said subject an amount of a composition of claim 132 effective to stimulate or enhance production of an antibody to at least one ganglioside selected from the group consisting of GM2, GD2, GD3 lactone, O-acetyl GD3 and GT3 and to thereby treat said melanoma in said subject.

134. (Currently Amended) A method of stimulating or enhancing production of an antibody to GM2, GD2, GD3 and GT3 in a subject which comprises administering to the subject an effective amount of a composition which comprises:

a) a conjugate of (i) ~~a ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion comprising an altered sphingosine base and~~ a derivative of a ganglioside, which ganglioside (1) is a GM2, GD2, GD3 lactone, O-acetyl GD3, or GT3 ganglioside and (2) comprises an unaltered sphingosine base, wherein the derivative differs from the ganglioside solely by having an altered sphingosine base which retains only C1 through C4 from the unaltered sphingosine base of the ganglioside, and (ii) Keyhole Limpet Hemocyanin, wherein the ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin by a stable amine bond between the C-4 carbon of the altered

sphingosine base and a nitrogen of an ε-aminolysyl group of Keyhole Limpet Hemocyanin ~~an immunogenic protein-based carrier~~;

b) QS-21; ~~a saponin derivable from the bark of a Quillaja saponaria Molina tree;~~ and

c) a pharmaceutically acceptable carrier;

wherein the amount of the conjugated ganglioside derivative is an amount between about 1 µg and about 200 µg, the amount of QS-21 ~~the saponin~~ is an amount between about 10 µg and about 200 µg, and ~~when the ganglioside is GM2, the GM2:Keyhole Limpet Hemocyanin~~ the ganglioside:Keyhole Limpet Hemocyanin molar ratio is from 200:1 to 1400:1, the ganglioside:Keyhole Limpet Hemocyanin, and the relative amounts of such conjugate and QS-21 is ~~such saponin being~~ effective to stimulate or enhance production in a subject of an antibody to GM2, GD2, GD3 and GT3, ~~whichever~~ the ganglioside, ~~is present as a~~ derivative of which is in the conjugate.[[,]]

~~wherein the ganglioside derivative is a derivative of a ganglioside selected from the group consisting of GM2, GD2, GD3 lactone, O-acetyl GD3 and GT3; and~~

~~wherein in the conjugate the ganglioside derivative is covalently bound to the Keyhole Limpet Hemocyanin by a stable amine bond between the C-4 carbon of the altered sphingosine base of the~~

~~altered ceramide portion of the ganglioside derivative and the nitrogen of an ε-aminolysyl group of the Keyhole Limpet Hemocyanin so as to thereby stimulate or enhance production of the antibody to GM2, GD2, GD3 and GT3 in the subject, whichever ganglioside is present as a derivative in the conjugate.~~

135. (Currently Amended) A method of treating a human subject having cancer which comprises administering to the subject an effective amount of a composition which comprises:

a) a conjugate of (i) ~~a ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion comprising an altered sphingosine base and~~ a derivative of a ganglioside, which ganglioside (1) is a GM2, GD2, GD3 lactone, O-acetyl GD3, or GT3 ganglioside and (2) comprises an unaltered sphingosine base, wherein the derivative differs from the ganglioside solely by having an altered sphingosine base which retains only C1 through C4 from the unaltered sphingosine base of the ganglioside, and (ii) Keyhole Limpet Hemocyanin~~, an immunogenic protein-based carrier~~;

b) QS-21 ~~a saponin derivable from the bark of a Quillaja saponaria Molina tree~~; and

c) a pharmaceutically acceptable carrier;

wherein the amount of the conjugated ganglioside derivative is an amount between about 1 µg and about 200 µg, the amount of ~~the saponin~~ QS-21 is an amount ~~of~~ between about 10 µg and about 200 µg, ~~and when the ganglioside is GM2, the GM2:Keyhole Limpet Hemocyanin~~ the ganglioside:Keyhole Limpet Hemocyanin molar ratio is from 200:1 to 1400:1, and the relative amounts of such conjugate and QS-21 is ~~such saponin being~~ effective to stimulate or enhance production in a subject of an antibody to GM2, GD2, GD3 and GT3, ~~whichever~~ the ganglioside, the ~~is present as a~~ derivative of which is present in the conjugate. [[;]]

~~wherein the ganglioside derivative is a derivative of a ganglioside selected from the group consisting of GM2, GD2, GD3 lactone, O-acetyl GD3 and GT3; and~~

~~wherein in the conjugate the ganglioside derivative is covalently bound to the Keyhole Limpet Hemocyanin by a stable amine bond between the C-4 carbon of the altered sphingosine base of the altered ceramide portion of the ganglioside derivative and the nitrogen of an e-aminolysyl group of the Keyhole Limpet Hemocyanin, so as to thereby stimulate or enhance production of the antibody to GM2, GD2, GD3 and GT3 in the subject, whichever ganglioside is present as a derivative in the conjugate.~~

136. (Previously Presented) The method of claim 135, wherein the cancer is of epithelial origin.

137. (Previously Presented) The method of claim 135, wherein the cancer is of neuroectodermal origin.

138. (Currently Amended) The method of claim 137, wherein the cancer of neuroectodermal origin is ~~a~~ melanoma.

139. (Previously Presented) The method of claim 134 or 135, wherein the administering is effected at two or more sites.

140. (Previously Presented) The method of claim 139, wherein the administering is effected at three sites.

141. (Previously Presented) The method of claim 134 or 135, wherein the composition is administered subcutaneously to said subject.

142. (Previously Presented) The method of claim 141, wherein the composition is administered to said subject at two-week intervals.

143. (Previously Presented) The method of claim 141, wherein the composition is administered to said subject at weekly intervals.

144. (Currently Amended) The method of claim 134 or 135, wherein the composition to be administered is

prepared prior to administration to the subject by mixing the conjugate and ~~the saponin~~ QS-21.

145. (Currently Amended) The method of claim 144, wherein the conjugate and ~~the saponin~~ QS-21 are mixed on the day of administration to the subject.

146. (Cancelled)